{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:19:28Z","timestamp":1761157168445,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has been described in some series. Our aim was to update the disease evolution after SAs withdrawal in a cohort of acromegalic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated 21 acromegalic patients previously included in a multicentre study (Ronchi et al. 2008), updating data at the last follow-up. We added further 8 patients selected for SAs withdrawal between 2008\u20132018. Pituitary irradiation represented an exclusion criterion. The withdrawal was suggested after at least 9 months of clinical and hormonal disease control. Clinical and biochemical data prior and after SAs withdrawal were analysed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the whole cohort (29 patients) mean age was 50\u2009\u00b1\u200914.9\u00a0years and 72.4% were females. In 69% pituitary surgery was previously performed. Overall, the median time of treatment before SAs withdrawal was 53\u00a0months (IQR\u2009=\u200924\u201384). At the last follow up in 2019, 23\/29 patients (79.3%) had a disease relapse after a median time of 6\u00a0months (interquartile range or IQR\u2009=\u20093\u201312) from the drug suspension, while 6\/29 (20.7%) were still on remission after 120\u00a0months (IQR\u2009=\u200966\u2013150). IGF-1 levels were significantly lower before withdrawal in patients with persistent remission compared to relapsing ones (IGF-1 SDS: -1.5\u2009\u00b1\u20090.6 vs -0.11\u2009\u00b1\u20091, <jats:italic>p<\/jats:italic>\u2009=\u20090.01). We did not observe any other difference between patients with and without relapse, including SAs formulation, dosage and treatment duration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A successful withdrawal of SAs is possible in a subset of well-controlled acromegalic patients and it challenges the concept that medical therapy is a lifelong requirement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01562-z","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T16:03:03Z","timestamp":1621526583000},"page":"2593-2599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-9293","authenticated-orcid":false,"given":"E.","family":"Sala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Carosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Del Sindaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mungari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cremaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Serban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"1562_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667\u2013674. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"Dekkers OM, Biermasz NR, Pereira AM et al (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61\u201367. https:\/\/doi.org\/10.1210\/jc.2007-1191","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167:189\u2013198. https:\/\/doi.org\/10.1530\/EJE-12-0084","journal-title":"Eur J Endocrinol"},{"key":"1562_CR4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR5","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558\u20132573. https:\/\/doi.org\/10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"key":"1562_CR6","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1210\/jcem.87.7.8665","volume":"87","author":"PU Freda","year":"2002","unstructured":"Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013\u20133018. https:\/\/doi.org\/10.1210\/jcem.87.7.8665","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR7","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1210\/endo.131.5.1385103","volume":"131","author":"SG Ren","year":"1992","unstructured":"Ren SG, Ezzat S, Melmed S, Braunstein GD (1992) Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 131:2479\u20132481. https:\/\/doi.org\/10.1210\/endo.131.5.1385103","journal-title":"Endocrinology"},{"key":"1562_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1530\/EJE-08-0822","volume":"160","author":"A Pokrajac","year":"2009","unstructured":"Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ (2009) Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 160:543\u2013548. https:\/\/doi.org\/10.1530\/EJE-08-0822","journal-title":"Eur J Endocrinol"},{"key":"1562_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1677\/erc.1.01191","volume":"13","author":"E Ferrante","year":"2006","unstructured":"Ferrante E, Pellegrini C, Bondioni S et al (2006) Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 13:955\u2013962. https:\/\/doi.org\/10.1677\/erc.1.01191","journal-title":"Endocr Relat Cancer"},{"key":"1562_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228\u2013252. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"},{"key":"1562_CR11","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1210\/jc.2005-0260","volume":"90","author":"PU Freda","year":"2005","unstructured":"Freda PU, Katznelson L, van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465\u20134473. https:\/\/doi.org\/10.1210\/jc.2005-0260","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1210\/jc.2004-1093","volume":"90","author":"JS Bevan","year":"2005","unstructured":"Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856\u20131863. https:\/\/doi.org\/10.1210\/jc.2004-1093","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2005-1704","volume":"91","author":"CL Ronchi","year":"2006","unstructured":"Ronchi CL, Varca V, Beck-Peccoz P et al (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121\u2013128. https:\/\/doi.org\/10.1210\/jc.2005-1704","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.03996.x","volume":"75","author":"M Tzanela","year":"2011","unstructured":"Tzanela M, Vassiliadi DA, Gavalas N et al (2011) Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf) 75:96\u2013102. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.03996.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1562_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-11-0738","volume":"166","author":"C Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez C, Vargas G, Gonz\u00e1lez B et al (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21\u201326. https:\/\/doi.org\/10.1530\/EJE-11-0738","journal-title":"Eur J Endocrinol"},{"key":"1562_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s12020-013-0094-9","volume":"46","author":"L Vilar","year":"2014","unstructured":"Vilar L, Fleseriu M, Naves LA et al (2014) Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial. Endocrine 46:577\u2013584. https:\/\/doi.org\/10.1007\/s12020-013-0094-9","journal-title":"Endocrine"},{"key":"1562_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11102-014-0608-3","volume":"18","author":"E Hatipoglu","year":"2015","unstructured":"Hatipoglu E, Bozcan S, Kadioglu P (2015) Discontinuation of somatostatin analogs while acromegaly is in long-term remission. Pituitary 18:554\u2013560. https:\/\/doi.org\/10.1007\/s11102-014-0608-3","journal-title":"Pituitary"},{"key":"1562_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0092","author":"C Alvarez-Escola","year":"2016","unstructured":"Alvarez-Escola C, Cardenas-Salas J (2016) Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-16-0092","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1562_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000446542","volume":"104","author":"A Casagrande","year":"2017","unstructured":"Casagrande A, Bronstein MD, Jallad RS et al (2017) Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event. Neuroendocrinology 104:273\u2013279. https:\/\/doi.org\/10.1159\/000446542","journal-title":"Neuroendocrinology"},{"key":"1562_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EJE-07-0488","volume":"158","author":"CL Ronchi","year":"2008","unstructured":"Ronchi CL, Rizzo E, Lania AG et al (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158:19\u201325. https:\/\/doi.org\/10.1530\/EJE-07-0488","journal-title":"Eur J Endocrinol"},{"key":"1562_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/jcem.85.2.6363","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526\u2013529. https:\/\/doi.org\/10.1210\/jcem.85.2.6363","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR22","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) A Consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"key":"1562_CR23","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1210\/jc.2016-1257","volume":"101","author":"P Chanson","year":"2016","unstructured":"Chanson P, Arnoux A, Mavromati M et al (2016) Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab 101:3450\u20133458. https:\/\/doi.org\/10.1210\/jc.2016-1257","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01562-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01562-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01562-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T21:14:22Z","timestamp":1636233262000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01562-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01562-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare that we have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Local Ethical Committee (Fondazione IRCCS Ca\u2019 Granda, Milan) approved the protocol study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients gave their informed written consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}